ENGN: enGene Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Historical context for ENGN
Across the 15 sessions after earlier ENGN headlines, the stock closed higher 7 times and lower 8 times, with a median move of 3.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ENGN | SPY |
|---|---|---|---|
| Jul 16, 2026 | enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones | +1.1% | -0.5% |
| Jun 18, 2026 | enGene Therapeutics downgraded by Morgan Stanley | -1.1% | +0.8% |
| Jun 15, 2026 | enGene Reports Second Quarter 2026 Financial Results and Provides Business Update | +9.3% | +1.8% |
| May 8, 2026 | enGene Therapeutics downgraded by Raymond James with a new price targetand 7 other headlines that session | -12.8% | +0.8% |
| May 7, 2026 | enGene Announces Updated Interim Results From LEGEND Pivotal Cohort | -80.6% | -0.3% |
| Apr 13, 2026 | WBB Securities initiated coverage on enGene Therapeutics with a new price target | +3.2% | +1.0% |
Quantisnow market dataNASDAQ
ENGN
enGene Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
Get push alerts for ENGN
Full ENGN profile on Quantisnow Follow ENGN and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time